Suven Life Sciences is a clinical stage biopharmaceutical company focused on discovering and developing innovative medicines for central nervous system (CNS) disorders. Suven has 5 clinical stage assets across focus areas: Masupirdine (SUVN-502) for the treatment of agitation in patients with dementia of the Alzheimer's type (Phase 3 study ongoing); Samelisant (SUVN-G3031) for excessive daytime sleepiness (EDS) in narcolepsy (Phase 2 study for EDS completed; Phase 2 study for Cataplexy and pivotal Phase 3 study for EDS are in planning); Ropanicant (SUVN911) for MDD (Phase 2b study ongoing); Usmarapride (SUVN-D4010) for cognitive disorders (Phase 2 study in planning), SUVN-I6107 for cognitive disorders (Phase 1 study ongoing). Suven has 7 projects in research pipeline across multiple indications.
Suven offers research services specializing in In-vitro Screening, Drug Metabolism & Pharmacokinetics, CNS Pharmacology, Toxicology and Safety Pharmacology, and Bioanalysis.